Hangzhou Fst Pharmaceutical Co.,Ltd

  1. (R)-N-Boc-2-羟甲基吗啉是RMC-6291的中间体（RMC-6291是一种口服有效的KRAS G12C(ON) 共价抑制剂，在KRASG12C(ON) 和亲环蛋白 A (CypA) 之间的肿瘤细胞内形成三复合物，用于治疗非小细胞肺癌、结直肠癌和晚期恶性实体瘤等。RMC-6291入围猎药人网站2023年度十大“明星”小分子榜单）；  2. (R)-N-Boc-2-羟甲基吗啉通过模板筛选用于制备Checkpoint激酶1的抑制剂，抑制原发肿瘤生长；  3. (R)-N-Boc-2-羟甲基吗啉还可用于实验室研发过程和化工医药研发过程中其他手性化...

Eicosanedioic acid is a building block for the synthesis of the GLP-1/GIP receptor dual agonist developed by Eli Lilly. This agonist can be used in the research of type 2 diabetes, diabetes-related neuropathy, and obesityIt is a non-cleavable ADC linker used for synthesizing antibody-drug conjugates (ADCs)...

The C20 fatty acid side chain is one of the key intermediates in the synthesis of the GLP-1/GIP receptor dual agonist developed by Eli Lilly, which can be used in the research of type 2 diabetes, diabetes-related neuropathy, and obesity

Established in 2002, Hangzhou FST Pharmaceutical focuses on advanced intermediates, APIs, and nutraceuticals. In 2022, it was acquired by Shanghai Eyougene Biotechnology, founded by top Fudan University graduates. Eyougene excels in digital CDMO services for advanced intermediates and new materials.  The group has R&D centers in Shanghai, Xi'an, and Wuhan, with 382 employees, including 169 R&D and QA professionals. The main products include cardiovascular, gastrointestinal, and weight control products. 
 Located in Jiande Hangzhou, the factory complies with GMP and holds ISO9001:2000, ISO14001, and OHSAS18001 certifications. Eyougene is committed to life science innovation for human health.
Here is the profile of Eyougene and FST.  You can find the introduction of company, technology, products,production system and business partners.